Fig. 1: The m⁶A profile in LPS-administrated cardiomyocytes.

A Cardiomyocytes (H9C2) was induced by LPS (10 μg/mL) to construct myocardial cell injury for septic myocardial cell injury investigation. B RT-PCR indicated the mRNA level of m⁶A methyltransferase METTL3 in cardiomyocytes with the increasing doses of LPS (0, 0.5, 1, 2, 5, 10 μg/mL) for 24 h. C Western blot analysis for the protein level in cardiomyocytes with the increasing doses of LPS (0, 0.5, 1, 2, 5, 10 μg/mL) for 24 h. D The m⁶A modification distribution in myocardial cell injury cardiomyocytes revealed by methylated RNA immunoprecipitation sequencing (MeRIP-Seq). E m⁶A metagene showed the m⁶A peak density in integral genome. F The candidate motifs. Biological experiments were performed in triplicate. Data were exhibited as Mean ± Standard Deviation (SD). **p < 0.01, *p < 0.05.